Abstract Manganese (Mn) is an essential metal for biological systems; however, occupational or clinical exposure to high levels of Mn can produce a neurological disorder called manganism. Oxidative stress and neuroinflammation play major roles in the Mn-induced neurodegeneration leading to dysfunction of the basal ganglia. We investigated the toxic effects of MnCl 2 in an immortalized rat brain endothelial cell line (RBE4) and the protective effects of the radical scavenging aminosalicylic acids, 5-aminosalicylic acid (5-ASA) and 4-aminosalicylic acid (4-PAS). Mn cytotoxicity was determined with 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) reduction and lactate dehydrogenase (LDH) activity. A significant decrease in MTT reduction concomitant with increased LDH release was noted in RBE4 cells exposed for 24 h to MnCl 2 (600 and 800 μM; p<0.0001). Our results establish that compared to 4-PAS, 5-ASA has greater efficacy in protecting RBE4 cells from Mn-induced neurotoxicity after preexposure to MnCl 2 800 μM (p<0.0001).
Introduction
Manganese (Mn) is an essential nutrient and it plays a fundamental role in cellular homeostasis. However, excessive Mn exposure causes neurotoxicity [4] . Clinical signs, such as Parkinsonism, characterized by an extrapyramidal movement disorder, commonly appear after a primarily psychiatric presentation (locura manganica) [15, 22] . Symptoms associated with manganism have been treated with limited efficacy with psychiatric and antiparkinsonian drugs [2, 10, 12] . In contrast to Parkinson's disease, Mn predominantly targets the globus pallidus [10] . Chelation serves to alleviate the acute symptoms, but there is little evidence to support that such therapy has chronic consequences (e.g., parkinsonism) [23] . Treatment of workers with occupational Mn-induced parkinsonism with ethylenediaminetetraacetic acid and antiparkinsonian drugs has led to improvement in clinical outcome [10] .
Herein, we utilized an established blood-brain barrier (BBB) model of immortalized rat brain endothelium 4 (RBE4) cells to evaluate Mn-induced cytotoxicity. The RBE4 cell line preserves features of the in vivo brain endothelium [5] , expressing a number of BBB transporters (Pglycoprotein) and endothelial markers (VIII-related antigen) [7] . RBE4 cells were derived from rat brain microvascular endothelial cells immortalized with the plasmid pE1A-neo, containing the E1A region of adenovirus 2 and a neomycinresistant gene [3, 24] .
Given the limited success in treating chronic states of Mninduced disease with antiparkinsonian drugs [10, 12, 25] , an increasing and immediate need exists for efficacious therapy against Mn-induced neurological impairment. We evaluated the efficacy of two carboxylic acids, 4-aminosalicylic acid (4-PAS) and 5-aminosalicylic acid Previous studies in rats demonstrated that treatment with 4-PAS markedly reduced brain Mn levels in animals subchronically and subacutely exposed to this metal [26, 34] .
However, 4-PAS is used as a second-line antituberculosis agent. Given (1) the indiscriminate use of antibiotics [8] that threatens their clinical efficacy, (2) the documented efficacy of 5-ASA as an antioxidant and anti-inflammatory agent [9, 19] , and (3) the role of reactive oxygen species and neuroinflammation in the etiology of Mn-induced neurotoxicity [16, 32] , the present study was designed to assess the efficacy of 5-ASA (vs. 4-PAS) in mitigating the cytotoxicity of this metal in RBE4 cells. LDH Toxicity Assay RBE4 cells were grown for 24 h, in 96-well culture plates, at 37°C, until confluency at a density of 1.48×10 5 cells/ml. Forty-five minutes after 4-PAS or 5-ASA or medium (control) treatment, cultures were processed in accordance with the LDH-based colorimetric assay [13] . The LDH released into the supernatant medium was analyzed according to the manufacturer's protocol (Promega) and quantified with an ELISA plate reader (Zenyth 3100) at 490 nm.
Materials and Methods

Chemicals
MTT Toxicity Assay
The MTT assay was performed according to the manufacturer's protocol (Sigma). After treatments (see above) and at the end of the respective incubation periods, 50 μl of MTT solution was added to each well, followed by 2 h incubation of the plates at 37°C in a CO 2 incubator. The reaction was terminated by the addition of 50 μl of MTT solubilization solution, and the results were quantified by measuring the absorbance at 570 nm. Treated samples are reported as percentage of viability in comparison to controls.
Statistical Analysis
All the results are expressed as means ± standard error of the mean (SEM) of three or more individual assays. Multiple comparisons were performed by utilizing one-way analysis of variance (ANOVA), followed by Bonferroni test for comparison of treatments with the controls. Results were analyzed by GraphPad Prism 4 (GraphPad Software, San Diego, CA); P values less than 0.05 were considered to be significant.
Results
4-PAS (2 mM)
was effective in protecting RBE4 cells treated for 24 h with 600 μM of MnCl 2 , as evidenced by a significant (p<0.0001) increase in MTT levels (Fig. 1b) and a decrease in LDH release (Fig. 1a) . Figure 2a shows that 1 and 2 mM 5-ASA significantly attenuated LDH release in RBE4 cells exposed for 24 h to 400 μM (p<0.0001 and p< 0.001), 600 μM (p<0.0001 and p<0.0001), or 800 μM (p< 0.001 and p<0.001) MnCl 2 . 5-ASA (1 and 2 mM) also significantly increased the conversion of MTT to formazan in RBE4 cells treated for 24 h with MnCl 2 within the tested concentration range (p<0.0001; Fig. 2b ).
Discussion
4-PAS and 5-ASA were assessed for their ability to attenuate Mn-induced cytotoxicity in RBE4 cells. The present study confirms that in cells exposed to MnCl 2 alone, the increase in LDH release is concordant with the decrease in MTT levels, corroborating previous reports [6, 14] . 5-ASA significantly decreased Mn cytotoxicity in RBE4 cells exposed to MnCl 2 for 24 h.
Several recent reports have suggested that inflammation and oxidative stress contribute to Mn-induced neurodegeneration [17, 27, 33] . The aminosalicylic acids, 4-PAS and 5-ASA, used provide an antioxidative protection through the deactivation of excited oxygen species [31] .
For the first time, our results show that 5-ASA has greater efficacy in protecting RBE4 cells from Mn-induced cytotoxicity in comparison to 4-PAS after preexposure to MnCl 2 800 μM (p<0.0001). The efficacy of 4-PAS has been ascribed to its role in reducing Mn concentrations in body fluids and brain, acting as a Mn-chelating agent [34] . A recent report in rats co-exposed to MnCl 2 and 4-PAS showed that 4-PAS was also effective in attenuating MnCl 2 -induced neurotoxicity [26] .
5-ASA is clinically used as an anti-inflammatory agent against intestinal mucosa and joint synovial inflammation [28] , where oxidative stress has been implicated [18] . Brain cells are especially susceptible to oxidative stress. 5-ASA showed protection against the oxidation in gerbil cortical synaptosome system caused by azobis(isobutyronitrile) and 2,2'-azobis(amidinopropane) dihydrochloride [11] .
Recent studies also showed that 5-ASA inhibits nuclear factor-κB (NF-κB) activation preventing the expression of genes encoding proinflammatory cytokines, chemokines, adhesion molecules, and inflammatory mediators [1] . In PC12 cells, Mn induced NF-κB [21] expression, lending support to the role of oxidative stress in its neurotoxicity. Pretreatment with either vitamin E or an NF-κB inhibitor protected against Mn toxicity in mesencephalic cells [20] . Notably, NF-κB is not a target of 4-PAS. Induction of Mn superoxide dismutase (MnSOD) activity by 5-ASA may also contribute to the therapeutic mechanism of 5-ASA [30] . Notably, MnSOD is not a target of 4-PAS.
Although 5-ASA protects RBE4 cells from the deleterious effects of Mn, it does not cross the BBB [29] . These findings suggest that new strategies to deliver it to the brain should be developed in order to prevent Mn-induced degeneration or other neurotoxicities associated with oxidative stress. Furthermore, we suggest the use of in vivo and in vitro models to study the effectiveness of other NF-κB inhibitors and/or enhancers of MnSOD activity that readily cross the BBB. These studies should profitably advance represent mean ± SEM (n=12).^^^p<0.0001 significantly different from control group; ***p<0.0001 and **p<0.001 significantly different from RBE4 cells exposed to the respective Mn 400, 600, and 800 μM group by one-way ANOVA followed by Bonferroni's multiple comparison tests Fig. 1 The effect of 4-PAS on MTT reduction (A) and membrane integrity (B) in RBE4 cells cultured in 96-well culture plates treated for 24 h with 400, 600 or 800 μM MnCl 2 or medium alone. After 24 h RBE4 cells were treated for 45 minutes with medium or 1 or 2 mM 4-PAS in DMSO. Values of MTT (% control) (A) and LDH (% control) (B) represent mean ± SEM (n=12).^^^p<0.0001 significantly different from control group, *** p<0.0001 significantly different from RBE4 cells exposed to the respective Mn 400, 600 and 800 μM group by one-way ANOVA followed by Bonferroni's multiple comparison tests strategies to control and mitigate the adverse effects of Mn in the brain.
